184 related articles for article (PubMed ID: 12773129)
1. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
van Tol KM; Jager PL; de Vries EG; Piers DA; Boezen HM; Sluiter WJ; Dullaart RP; Links TP
Eur J Endocrinol; 2003 Jun; 148(6):589-96. PubMed ID: 12773129
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.
Roelants V; Nayer PD; Bouckaert A; Beckers C
Eur J Nucl Med; 1997 Jul; 24(7):722-7. PubMed ID: 9211756
[TBL] [Abstract][Full Text] [Related]
5. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
[TBL] [Abstract][Full Text] [Related]
6. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
7. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
Kim WG; Ryu JS; Kim EY; Lee JH; Baek JH; Yoon JH; Hong SJ; Kim ES; Kim TY; Kim WB; Shong YK
J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
[TBL] [Abstract][Full Text] [Related]
8. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
Koh JM; Kim ES; Ryu JS; Hong SJ; Kim WB; Shong YK
Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
[TBL] [Abstract][Full Text] [Related]
9. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
10. [Investigating patients with differentiated thyroid carcinoma and elevated serum thyroglobulin but negative whole-body scan].
Rosário PW; Maia FC; Barroso AL; Purisch S
Arq Bras Endocrinol Metabol; 2005 Apr; 49(2):246-52. PubMed ID: 16184253
[TBL] [Abstract][Full Text] [Related]
11. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.
Pacini F; Agate L; Elisei R; Capezzone M; Ceccarelli C; Lippi F; Molinaro E; Pinchera A
J Clin Endocrinol Metab; 2001 Sep; 86(9):4092-7. PubMed ID: 11549631
[TBL] [Abstract][Full Text] [Related]
12. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma].
Caresia AP; Castell Conesa J; Obiols Alfonso G; Pifarré Montaner P; Negre Busó M; García Alonso C; Galofré Mora P; Mesa Manteca J
Rev Esp Med Nucl; 2006; 25(4):236-41. PubMed ID: 16827986
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
15. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH.
Cohen O; Dabhi S; Karasik A; Zila Zwas S
Eur J Endocrinol; 2004 Mar; 150(3):285-90. PubMed ID: 15012612
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan.
Saghari M; Gholamrezanezhad A; Mirpour S; Eftekhari M; Takavar A; Fard-Esfahani A; Fallahi B; Beiki D
Nucl Med Commun; 2006 Jul; 27(7):567-72. PubMed ID: 16794517
[TBL] [Abstract][Full Text] [Related]
18. [Serum thyroglobulin and whole-body scanning as markers in the follow-up of differentiated thyroid carcinomas].
Degrossi OJ; Rozados IB; Damilano S; Degrossi EB; de Ganino L; Pinkas M; García del Río H; Artagaveytía D
Medicina (B Aires); 1991; 51(4):291-5. PubMed ID: 1821916
[TBL] [Abstract][Full Text] [Related]
19. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma?
Ronga G; Fiorentino A; Paserio E; Signore A; Todino V; Tummarello MA; Filesi M; Baschieri I
J Nucl Med; 1990 Nov; 31(11):1766-71. PubMed ID: 2121913
[TBL] [Abstract][Full Text] [Related]
20. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
